Bausch Health Companies Inc. (NYSE:BHC) Receives $7.75 Average PT from Analysts

Shares of Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) have earned a consensus rating of "Hold" from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $7.75.

A number of research analysts have weighed in on BHC shares. Evercore ISI upgraded shares of Bausch Health Companies to a "hold" rating in a research report on Tuesday, October 15th. StockNews.com raised shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Friday, October 25th. Finally, Royal Bank of Canada raised their price objective on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a "sector perform" rating in a research note on Friday, November 1st.

Bausch Health Companies Price Performance

Shares of NYSE BHC traded up $0.09 during mid-day trading on Thursday, hitting $7.66. 983,135 shares of the company's stock traded hands, compared to its average volume of 1,484,923. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The company's 50-day moving average is $7.99 and its two-hundred day moving average is $7.44. The company has a market capitalization of $2.77 billion, a P/E ratio of -15.95 and a beta of 0.69.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.10. The business had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.42 billion. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The company's revenue for the quarter was up 12.2% on a year-over-year basis. During the same period last year, the company earned $1.03 EPS. Equities analysts anticipate that Bausch Health Companies will post 3.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Companies

Institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC bought a new position in Bausch Health Companies in the second quarter worth approximately $35,000. MQS Management LLC purchased a new stake in shares of Bausch Health Companies in the 2nd quarter worth $71,000. Kendall Capital Management bought a new position in shares of Bausch Health Companies during the 2nd quarter worth $87,000. Brown Brothers Harriman & Co. bought a new position in shares of Bausch Health Companies during the 2nd quarter worth $109,000. Finally, Seven Eight Capital LP purchased a new position in shares of Bausch Health Companies during the second quarter valued at $173,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.